Congenital hypothyroidism (CH), the most common congenital endocrine disorder, is one of the most preventable causes of mental retardation in children (
1). Hypothyroidism is asymptomatic at birth in 95% of cases and rarely presents with symptoms such as swelling around the eyes, drowsiness, large tongue, and prolonged jaundice (
2). Timely diagnosis of this disease is crucial because the first few years of life are critical for brain development, which depends on thyroid hormones. As mentioned, this disease rarely shows symptoms at birth. However, if diagnosed early, its irreversible and irreparable complications can be avoided. The causes of CH include disorders in the development of the thyroid gland and in the synthesis of thyroid hormones (
3). Congenital hypothyroidism is one of the most significant health problems in Iran, with an average incidence of 2.6 per 1000 live births (
4).
Adherence to medications is crucial for the treatment of children with CH. In addition to the early detection of CH in newborns, successful treatment outcomes are possible if parents of hypothyroid children have higher medication adherence. In fact, compliance with medication is essential to improve the neurodevelopmental outcomes of these children (
5).
Early detection and timely treatment of neonates with CH are crucial, as initiating treatment before the 20th day after birth is associated with better outcomes (
6). We previously assessed the physical development and intelligence quotients of hypothyroid patients diagnosed through the national newborn screening program in Iran. The results showed that the intelligence quotient and physical development of affected children at the age of 6 years were almost similar to those of healthy children of the same age (
7).
According to the national guidelines for newborn screening in Iran, all children with congenital hypothyroidism should have their blood thyroid hormone levels brought within the normal range as soon as possible by prescribing Levothyroxine. The goal of the treatment is to normalize the thyroxine concentration in the baby's serum within 2 weeks and TSH within a month. The initial amount of Levothyroxine prescribed is 10 to 15 micrograms per kilogram of the baby's weight. After crushing the tablet, the powder is dissolved in water or breast milk and fed to the baby (
8,
9).
The level of cooperation and treatment compliance of families of affected children is a crucial component of the success of this program. Although almost 18 years have passed since the implementation of the newborn hypothyroidism screening program in Iran (
4), no study has been conducted at the provincial or national level to measure compliance with treatment for this disease.